These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 19598278)
21. Phenotypic & genotypic variants of Pseudomonas aeruginosa isolated from children with cystic fibrosis in India. Agarwal G; Kapil A; Kabra SK; Chandra R; Das B; Diwedi SN Indian J Med Res; 2002 Aug; 116():73-81. PubMed ID: 12592994 [TBL] [Abstract][Full Text] [Related]
22. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Amin R; Lam M; Dupuis A; Ratjen F Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727 [TBL] [Abstract][Full Text] [Related]
23. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. Schelstraete P; Deschaght P; Van Simaey L; Van Daele S; Haerynck F; Vaneechoutte M; De Baets F J Cyst Fibros; 2010 Mar; 9(2):99-103. PubMed ID: 20004150 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511 [TBL] [Abstract][Full Text] [Related]
25. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. Etherington C; Hall M; Conway S; Peckham D; Denton M J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280 [TBL] [Abstract][Full Text] [Related]
26. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Drenkard E; Ausubel FM Nature; 2002 Apr; 416(6882):740-3. PubMed ID: 11961556 [TBL] [Abstract][Full Text] [Related]
27. Familial concordance of phenotype and microbial variation among siblings with CF. Picard E; Aviram M; Yahav Y; Rivlin J; Blau H; Bentur L; Avital A; Villa Y; Schwartz S; Kerem B; Kerem E Pediatr Pulmonol; 2004 Oct; 38(4):292-7. PubMed ID: 15334505 [TBL] [Abstract][Full Text] [Related]
28. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484 [TBL] [Abstract][Full Text] [Related]
29. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Nixon GM; Armstrong DS; Carzino R; Carlin JB; Olinsky A; Robertson CF; Grimwood K J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046 [TBL] [Abstract][Full Text] [Related]
30. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Saiman L Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923 [TBL] [Abstract][Full Text] [Related]
31. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Lechtzin N; John M; Irizarry R; Merlo C; Diette GB; Boyle MP Respiration; 2006; 73(1):27-33. PubMed ID: 16113513 [TBL] [Abstract][Full Text] [Related]
32. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. Hansen CR; Pressler T; Koch C; Høiby N J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679 [TBL] [Abstract][Full Text] [Related]
33. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. Hogardt M; Hoboth C; Schmoldt S; Henke C; Bader L; Heesemann J J Infect Dis; 2007 Jan; 195(1):70-80. PubMed ID: 17152010 [TBL] [Abstract][Full Text] [Related]
34. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. García-Castillo M; del Campo R; Baquero F; Morosini MI; Turrientes MC; Zamora J; Cantón R Clin Microbiol Infect; 2011 May; 17(5):704-11. PubMed ID: 20673272 [TBL] [Abstract][Full Text] [Related]
35. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P; Widmer F; Middleton PG; Iredell J; George AM FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356 [TBL] [Abstract][Full Text] [Related]
36. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Elborn JS; Henig NR Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707 [TBL] [Abstract][Full Text] [Related]
37. [Evaluation of a new E-test method for antimicrobial sensitivity testing of Pseudomonas aeruginosa isolates from cystic fibrosis]. Zebouh M; Thomas C; Honderlick P; Lemee L; Segonds C; Wallet F; Husson MO Pathol Biol (Paris); 2005; 53(8-9):490-4. PubMed ID: 16087300 [TBL] [Abstract][Full Text] [Related]
38. Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Alcalá-Franco B; Montanari S; Cigana C; Bertoni G; Oliver A; Bragonzi A J Antimicrob Chemother; 2012 Apr; 67(4):962-9. PubMed ID: 22294647 [TBL] [Abstract][Full Text] [Related]
39. Pseudomonas aeruginosa: antibiotic susceptibility and genotypic characterization of strains isolated in the intensive care unit. Bertrand X; Thouverez M; Patry C; Balvay P; Talon D Clin Microbiol Infect; 2001 Dec; 7(12):706-8. PubMed ID: 11843917 [TBL] [Abstract][Full Text] [Related]
40. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients. Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]